SirtAct
Sirt1 activator / Sirt1 activator (233% at 10 μM)1 Suppresses TNFα release from THP-1 cells and stimulates adipogenesis in 3T3L1 cells1. SIRT1 stimulation by SirtAct leads to decreased tissue factor mediated thrombogenicity in mice2. Inhibits NFκB activation and reduces inflammatory cytokine production in lamina propria mononuclear cells from IBD patients3. Prevents and cures experimental colitis in a mouse model3.
Biochemicals & reagents
839699-72-8
CAY10591
1) Nayagam et al. (2006), SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin sensitizing agents; J. Biomol. Screen., 11 959 2) Barbieri et al. (2012), Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner; Circulation, 126 1373 3) Caruso et al. (2014), Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut; Mucosal Immunol., May 21 Epub.
-20°C
TARGET: Protein deacetylase -- PATHWAY: NFkappaB; Cytokine; Chromatin; Posttranslational modification -- RESEARCH AREA: Epigenetics -- DISEASE AREA: Inflammation; Diabetes